Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05459922 · ClinicalTrials.gov registry record · NA
Adjunctive Bright Light Therapy for Opioid Use Disorder
A NA study of Opioid Use Disorder and Sleep Disturbance, sponsored by Arizona State University.
- Recruiting
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT05459922: Recruiting NA study of Opioid Use Disorder and Sleep Disturbance, sponsored by Arizona State University.
NCT05459922 is a NA study of Opioid Use Disorder and Sleep Disturbance that is actively recruiting participants, run by Arizona State University. The registered enrollment target is 23 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05459922, a NA study of Opioid Use Disorder and Sleep Disturbance, is actively recruiting participants, sponsored by Arizona State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators propose to conduct a pilot single-blind, parallel arm, randomized placebo-controlled trial evaluating the feasibility, acceptability, and preliminary efficacy of bright light therapy on reward system functioning among patients undergoing medication-assisted treatment for opioid use disorder.
Primary Outcome
From enrollment to post-treatment assessment
Conditions Studied
Interventions
- DEVICE Wearable bright light therapy device
- DEVICE Wearable placebo light therapy device
Study Locations (1)
Arizona
- Arizona State University - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-10-23 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT05459922 shows while recruiting
NCT05459922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Wearable bright light therapy device is the first listed.
NCT05459922 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05459922 about?
NCT05459922 is a clinical study titled "Adjunctive Bright Light Therapy for Opioid Use Disorder". Investigators propose to conduct a pilot single-blind, parallel arm, randomized placebo-controlled trial evaluating the feasibility, acceptability, and preliminary efficacy of bright light therapy on reward system functioning among patients undergoing medication-assisted treatment for opioid use dis...
What is the current status of trial NCT05459922?
This trial is currently recruiting. It is a NA study. The enrollment target is 23 participants. The study started on 2022-10-23. Estimated completion is 2026-05-31.
What conditions does trial NCT05459922 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Sleep Disturbance.
What interventions are being tested in trial NCT05459922?
The interventions under investigation include: Wearable bright light therapy device (DEVICE), Wearable placebo light therapy device (DEVICE).
Who is sponsoring clinical trial NCT05459922?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05459922 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05459922's enrollment target sits among peer trials
23 228th of 257 higher than 30 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI